A mixed-methods survey study indexed on Europe PMC reports that adults using glucagon-like peptide-1 receptor agonists described changes in mental wellbeing, food preoccupation and substance use alongside the weight loss. The authors argue that judging treatment success on weight and metabolic numbers alone misses most of what patients say is happening.

GLP-1 receptor agonists are the drug class behind the current weight-management boom, used in both diabetes care and obesity treatment. The researchers ran an international online survey of adults who had taken one for any indication, collecting responses between September 2024 and April 2025, and analyzed the open-ended answers with reflexive thematic analysis.

Key results

A total of 829 people completed the survey, predominantly middle-aged women in Australia, the United States and the United Kingdom. Weight loss was the reason for starting treatment for 60 percent, and diabetes management for 17 percent.

Side effects were close to universal: 88 percent reported at least one adverse effect, yet two-thirds said those effects had minimal or no impact on life satisfaction. That gap is the most interesting number in the paper, and it is the one a trial measuring discontinuation rates alone would never surface.

The substance use numbers

Reduced substance use after starting treatment was reported by 72 percent of alcohol users, 33 percent of recreational drug users and 25 percent of smokers or vapers. These are self-reported changes in a self-selected sample, not a measured outcome, but the alcohol figure is large enough to explain why this question keeps turning up in GLP-1 research.

The qualitative side produced three themes: weight management success, treatment-related challenges, and positive changes beyond weight. Participants frequently described the drugs as transformative despite emotional, financial and practical burdens, with improved relationships with food and reduced "food noise" among the commonly reported changes.

Limitations

This is an online survey with no control group, no randomization and no verification of what participants took or what happened to them. Respondents chose to take part, which tends to favor people with something to report, and the sample skewed heavily toward middle-aged women in three English-speaking countries.

The authors note experiences varied, and the paper is posted as a preprint. Nothing here establishes that the drugs caused the reported changes.

Bottom line

The authors conclude that GLP-1 treatment is associated with a broad range of patient-reported outcomes beyond weight, and recommend evaluating success with a multidimensional, patient-centered framework. Whether routine monitoring of those outcomes actually improves treatment sustainability is the question this study raises rather than answers.